Detoxified TLR4 Agonist with Systemic Antitumor Activity
Native bacterial lipopolysaccharides (LPS) are potent activators of the innate immune system but their clinical use as
systemic anticancer agents has been severely limited by toxicity. This study investigates a combined strategy based on
liposomal encapsulation and chemical detoxification to develop a systemically active and well-tolerated
TLR4 agonist.
Why TLR4 Activation Is a Key Target in Cancer Immunotherapy
Toll-like receptor 4 (TLR4) is expressed on antigen-presenting cells such as dendritic cells, monocytes, and macrophages.
Its activation promotes cytokine production, antigen presentation, and the initiation of durable antitumor immune
responses. Harnessing TLR4 signaling remains an attractive approach to enhance innate and adaptive immunity in oncology.
Overcoming the Toxicity of Native LPS
Liposomal Encapsulation Strategy
The study demonstrates that encapsulating LPS into liposomes preserves its immunostimulatory and antitumor properties
while significantly reducing systemic inflammation. Liposomal LPS preferentially localizes to immune-rich organs such as
the spleen and enhances the efficacy of therapeutic antibodies in preclinical lymphoma models.
Chemical Detoxification: Development of MP-LPS
A chemically detoxified LPS derivative, named MP-LPS, was generated from Bordetella pertussis. This molecule
retains the core oligosaccharide and lipid A structure while removing a phosphate group, resulting in a strong reduction
of pro-inflammatory cytokine induction and pyrogenicity compared with native LPS.
Preclinical Antitumor Efficacy
Both liposomal LPS and liposomal MP-LPS demonstrated robust antitumor activity across multiple murine cancer models.
The formulations showed intrinsic antitumor effects and strong immunoadjuvant activity when combined with monoclonal
antibodies or immune checkpoint inhibitors.
- Significant tumor growth delay in immunocompetent models
- Enhanced efficacy of anti-CD20 antibodies in lymphoma models
- Synergy with anti-PD-1 therapy in colorectal cancer models
Improved Safety and Tolerance Profile
Chemical detoxification reduced inflammatory cytokine production by more than two orders of magnitude compared with
native LPS. Liposomal formulation further improved tolerance, notably reducing pyrogenicity and systemic inflammatory
responses.
A phase 1 tolerance study conducted in healthy dogs confirmed systemic tolerability at high doses, with only transient
and reversible clinical and biological effects.
Mechanism of Action: TRIF-Biased TLR4 Signaling
Mechanistic analyses revealed that MP-LPS preferentially activates the TRIF-dependent TLR4 pathway, rather than
the strongly pro-inflammatory MyD88 pathway. This signaling bias is associated with effective immune activation combined
with reduced systemic toxicity.
In addition, liposomal MP-LPS was shown to repolarize M2 macrophages toward an M1 phenotype, promoting a tumor
microenvironment favorable to antitumor immunity.
Translational Relevance
This work supports the development of a systemically administered TLR4 agonist capable of overcoming the historical
toxicity barriers of LPS-based therapies. By combining detoxification chemistry with clinically validated liposomal
technology, liposomal MP-LPS emerges as a promising immunotherapy candidate for the treatment of disseminated cancers.